Proactive Investors - Run By Investors For Investors

Midatech starts first clinical trial using gold nanoparticles

The MTX102 vaccine uses Midatech's primary platform GNP technology.
picture of someone being injected
First time Midatech's GNP technology has been used on people

Midatech Pharma Plc (LON:MTPH Nasdaq:MTP) has started a phase I safety trial for a diabetes vaccine (MTX102) that uses its gold nanoparticle (GNP) technology.

It was the first investigational use of the GNP technology in humans and as an immunotherapy said Jim Phillips, Midatech’s chief executive.

Results from the study are expected in 2017, where Midatech will also assess the nano-vaccine’s potential in cancer applications. 

The MTX102 vaccine uses Midatech's primary platform GNP technology.

“GNPs bind to small antigens which generate a tolerogenic response when injected into the skin, turning down the immune response against the insulin producing cells which cause type 1 diabetes,”  it said.

As well as safety and tolerance, the study will also assess the feasibility of delivering GNP via microneedles and the scale and nature of immune responses generated in the body.

The trial will be conducted in Cardiff and Linköping in Sweden. 

 “We are hopeful that this trial will demonstrate the broad applicability of our technology and is exciting for the future of our R&D pipeline,” Phillips added.

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use